Endologix, Inc. to Host an Investor Conference Call to Discuss its Nellix® Endovascular Aneurysm Sealing System Presentation...
April 24 2017 - 4:01PM
Business Wire
Endologix, Inc. (Nasdaq: ELGX), a developer and marketer of
innovative treatments for aortic disorders, today announced that
Dr. Jeffrey Carpenter’s submission “Refinement of the IFU for the
Nellix® System for Endovascular Aneurysm Sealing Based Upon
Outcomes From the EVAS FORWARD IDE Trial” has been accepted for a
plenary presentation at the Society of Vascular Surgery (“SVS”)
Annual Meeting on June 3, 2017 in San Diego, California. The
presentation will take place during the Late Breaking session from
9:00 to 10:00 a.m. PT (12:00 to 1:00 p.m. ET).
The Company will host an investor call on the same day at 12:00
p.m. PT (3:00 p.m. ET) to review the presentation.
To participate in the conference call, dial 888-283-6901
(domestic) or 719-457-2552 (international).
This conference call will also be webcast and can be accessed
from the “Investors” section of the Company’s website at
www.endologix.com. The webcast replay of the call will be available
at the same site approximately one hour after the end of the
call.
A recording of the call will also be available from 3:00 p.m. PT
(6:00 p.m. ET) on Saturday, June 3, 2017, until 8:59 p.m. PT (11:59
p.m. ET) on Saturday, June 10, 2017. To hear this recording, dial
844-512-2921 (domestic) or 412-317-6671 (international) and enter
the passcode 7744943.
About Endologix, Inc.
Endologix, Inc. develops and manufactures minimally invasive
treatments for aortic disorders. The Company's focus is
endovascular stent grafts for the treatment of abdominal aortic
aneurysms (AAA). AAA is a weakening of the wall of the
aorta, the largest artery in the body, resulting in a balloon-like
enlargement. Once AAA develops, it continues to enlarge and,
if left untreated, becomes increasingly susceptible to rupture. The
overall patient mortality rate for ruptured AAA is
approximately 80%, making it a leading cause of death in the
United States. For more information,
visit www.endologix.com.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170424006376/en/
Endologix, Inc.Vaseem Mahboob, CFO, 949-595-7200 (Investors)
Endologix (NASDAQ:ELGX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Endologix (NASDAQ:ELGX)
Historical Stock Chart
From Sep 2023 to Sep 2024